Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Apellis (Nasdaq: APLS) will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
The live webcast will be posted on the company’s Events and Presentations investor page and a replay will be available for approximately 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – APLS
In the Feb 23 session, APLS gained 0.85%, reflecting a mild positive market reaction. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Scientific meeting data | Positive | +1.9% | Multiple Macula Society oral presentations including five-year GALE extension results. |
| Feb 10 | Earnings call scheduling | Neutral | -1.1% | Announcement of Q4 and full-year 2025 earnings call and webcast logistics. |
| Jan 12 | Commercial update | Positive | -15.0% | Preliminary 2025 revenues, strong SYFOVRE uptake, EMPAVELI growth, and pipeline plans. |
| Jan 05 | Conference presentation | Neutral | -3.8% | Planned J.P. Morgan Healthcare Conference presentation and webcast availability. |
| Dec 03 | Phase 3 trial results | Positive | +2.9% | Positive Phase 3 VALIANT outcomes for EMPAVELI in C3G and IC-MPGN published in NEJM. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and scientific updates have often coincided with gains, while strong commercial or strategic updates have previously seen at least one notable negative reaction.
Over the last few months, Apellis has combined scientific visibility, commercial updates, and pipeline progress. On Dec 3, positive Phase 3 VALIANT results and prior July 28, 2025 FDA approval saw shares rise 2.86%. A J.P. Morgan update on Jan 12 reported strong 2025 revenue and cash metrics yet shares fell 15.02%. Conference-related announcements on Jan 5 and Feb 10 produced modest declines, while Macula Society presentation news on Feb 19 aligned with a 1.89% gain. Today’s conference appearance fits this cadence of frequent investor-facing events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
